Paradigm Biocapital Advisors LP Erasca, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Erasca, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 11,907,182 shares of ERAS stock, worth $18.6 Million. This represents 0.71% of its overall portfolio holdings.
Number of Shares
11,907,182
Previous 10,802,354
10.23%
Holding current value
$18.6 Million
Previous $14.8 Million
2.18%
% of portfolio
0.71%
Previous 0.76%
Shares
5 transactions
Others Institutions Holding ERAS
# of Institutions
149Shares Held
217MCall Options Held
258KPut Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$35.5 Million1.52% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.3MShares$31.7 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$27.9 Million4.49% of portfolio
-
Logos Global Management LP San Francisco, CA15MShares$23.4 Million2.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$22.6 Million0.63% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $191M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...